Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Drug Safety Office Is “Separate, But Unequal,” Senate Committee Says

Executive Summary

A Senate committee investigation into FDA's handling of pediatric suicidality concerns with antidepressant drugs is focusing on the "unequal" status of the Office of Drug Safety and the Office of New Drugs

You may also be interested in...



FDA Office Of Drug Safety Acting Director Is Ralph Lillie

FDA Emergency Preparedness Officer Ralph Lillie is serving as acting director of the Office of Drug Safety in the Center for Drug Evaluation & Research as of Jan. 23

FDA Office Of Drug Safety Acting Director Is Ralph Lillie

FDA Emergency Preparedness Officer Ralph Lillie is serving as acting director of the Office of Drug Safety in the Center for Drug Evaluation & Research as of Jan. 23

Vioxx Hearing May Be Sign Of Things To Come Under Medicare Rx

The Senate Finance Committee should continue to review FDA's drug safety procedures in light of the upcoming expansion of the Medicare program, Ranking Democrat Max Baucus (D-Mont.) maintained during the committee's Nov. 18 hearing on Vioxx

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel